Exelixis, Inc. EXEL
Composite 73/100; the shares have moved about 36% annualised. Names that move more contribute more risk for the same amount invested, and our composite reflects how strong the evidence for this one is right now.
Valuation ranks 48/100 — a slight mark against it.
Balance-sheet strength ranks 87/100 — a strong point in its favour. Quality ranks 82/100 — a strong point in its favour. Momentum ranks 79/100 — a strong point in its favour.
Valuation ranks 48/100 — a slight mark against it.
What the company does Exelixis is an oncology-focused biotech commercializing cabozantinib-based therapies (CABOMETYX, COMETRIQ) for advanced renal cell and medullary thyroid cancers, plus MEK inhibitor COTELLIC and hypertension drug MINNEBRO in Japan. Its pipeline includes zanzalintinib, USP1 inhibitor XL309, and ADC XB010 targeting 5T4.
Key financials Exelixis posts strong profitability with ROE 41%, ROA 22%, and ROCE 44.4%, supported by gross margins of 96.4% and net margins of 35.1%. Revenue grew 10% and EPS 43.6%, with a clean balance sheet (debt/equity 0.09, net debt/EBITDA –0.62) and solid liquidity (current ratio 3.26).
Stock health The stock shows robust momentum: +25.24% over 3m, +31.20% over 6m, and +51.52% over 12m, with an RSI(14) of 55.70. Sideravia rates overall quality at 75.1 (Excellent), citing high scores in Strength (94.2) and Quality (87.8) but middling Valuation (53.4).
Price vs fair value The stock trades at a **discount of 16.20%** to our fair-value estimate of 65.03 and a **PREMIUM of 6.97%** to the 12-month analyst target of 52.07. - Shares are up 51.52% over 12m despite being 2.78% below the 52-week high (Sideravia). - Analysts (n=15) collectively set a 12-month target implying a 6.97% PREMIUM to today’s price (Market data). - The valuation percentile of 53.4/100 suggests fair value, yet momentum remains strong (Sideravia).
Looking forward Pipeline catalysts (zanzalintinib, XL309, XB010) and cabozantinib label expansions could drive upside. Consensus fwd P/E of 17.51 and PEG of 3.73 reflect growth expectations, but execution risks remain tied to trial outcomes and competition in RCC and melanoma.
This is not investment advice. Sideravia provides automated, data-driven analysis for information and education only. Nothing on this page is a personal recommendation or an invitation to buy or sell any security, and it does not consider your objectives or financial situation. Assessments are generated by rules applied uniformly to every covered stock — how our scores work.
Data as of 2026-09-03, compiled from third-party sources; errors and delays are possible and figures are not warranted. Investing puts your capital at risk; past performance does not predict future results. We publish our full track record, including the calls that lost, and our conflicts of interest.